Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001295
First received: November 3, 1999
Last updated: March 14, 2014
Last verified: October 2013
  Purpose

This protocol is to provide continuing medical/surgical/radio-therapeutic care, treatment and follow-up for NCI patients not currently entered on an active research protocol. No investigational treatments will be administered on this protocol.


Condition
Acquired Immunodeficiency Syndrome
Neoplasm
Skin Disease
HIV Infections

Study Type: Observational
Official Title: Continuing Treatment for Children and Adults in the Center for Cancer Research

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Enrollment: 2143
Study Start Date: January 1992
Detailed Description:

Background:

It may be in the interest of the CCR to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol.

Objective:

To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol.

Eligibility:

Subjects who have been previously enrolled on and received treatment according to an approved CCR research protocol. (clinical trial)

It is in the best interest of the subject and the CCR for the subject to continue to receive standard care and follow-up at the NIH.

Design:

Medical/surgical/radiotherapeutic care, treatment and follow-up is provided for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on an active research protocol.

No investigational treatments will be administered. This protocol is not be used as a platform to perform pilot studies of off-label uses for standard agents.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Subjects of any age who have been previously enrolled and treated on an approved CCR research treatment protocol.

It is in the best interests of the subject and the CCR for the subject to continue to receive treatment and follow-up at the NIH.

The subject or guardian signs the informed consent and agrees to the proposed treatment regimen.

EXCLUSION CRITERIA:

Subjects who have not been previously treated on a CCR research treatment protocol.

Subjects who are receiving an investigational therapy.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001295

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Caryn Steakley, R.N. National Cancer Institute (NCI)
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00001295     History of Changes
Other Study ID Numbers: 920094, 92-C-0094
Study First Received: November 3, 1999
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Standard Care
Follow-Up
Bridge Protocol

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Neoplasms
Immunologic Deficiency Syndromes
Skin Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on July 10, 2014